MUC16 and COVID-19: Our findings positioned CA125 as an independent biomarker of fatal outcomes in patients hospitalized for COVID-19, above the classical inflammation markers described in the literature (ferritin, procalcitonin, LDH, and C-reactive protein) (32, 33) or biomarkers of myocardial damage (T troponin and pro-BNP) (9).